Bradley, S. J. , Tobin, A. B. and Prihandoko, R. (2018) The use of chemogenetic approaches to study the physiological roles of muscarinic acetylcholine receptors in the central nervous system. Neuropharmacology, 136(Part C), pp. 421-426. (doi: 10.1016/j.neuropharm.2017.11.043) (PMID:29191752)
|
Text
153427.pdf - Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. 1MB |
Abstract
Chemical genetic has played an important role in linking specific G protein-coupled receptor (GPCR) signalling to cellular processes involved in central nervous system (CNS) functions. Key to this approach has been the modification of receptor properties such that receptors no longer respond to endogenous ligands but rather can be activated selectively by synthetic ligands. Such modified receptors have been called Receptors Activated Solely by Synthetic Ligands (RASSLs) or Designer Receptors Exclusively Activated by Designer Drugs (DREADDs). Unlike knock-out animal models which allow detection of phenotypic changes caused by loss of receptor functions, RASSL and DREADD receptors offer the possibility of rescuing "knock-out" phenotypic deficits by administration of the synthetic ligands. Here we describe the use of these modified receptors in defining the physiological role of GPCRs and validation of receptors as drug targets.
| Item Type: | Articles |
|---|---|
| Keywords: | Central nervous system, chemical genetics, designer receptors activated by designer drugs, muscarinic receptors, receptors activated solely by synthetic ligands. |
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Prihandoko, Dr Rudi and Tobin, Andrew and Bradley, Dr Sophie |
| Authors: | Bradley, S. J., Tobin, A. B., and Prihandoko, R. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Molecular Biosciences |
| Journal Name: | Neuropharmacology |
| Publisher: | Elsevier |
| ISSN: | 0028-3908 |
| ISSN (Online): | 1873-7064 |
| Published Online: | 27 November 2017 |
| Copyright Holders: | Copyright © 2017 Elsevier Ltd. |
| First Published: | First published in Neuropharmacology 136(Part C):421-426 |
| Publisher Policy: | Reproduced in accordance with the publisher copyright policy |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information